Clinical Trials Logo

Carcinoma, Renal Cell clinical trials

View clinical trials related to Carcinoma, Renal Cell.

Filter by:
  • Active, not recruiting  
  • Page 1 ·  Next »

NCT ID: NCT05899049 Active, not recruiting - Clinical trials for Carcinoma, Renal Cell

A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, vs Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)-China Extension Study

Start date: July 27, 2022
Phase: Phase 3
Study type: Interventional

The goal of this China extension study is to evaluate the efficacy and safety of pembrolizumab plus belzutifan plus lenvatinib or pembrolizumab/quavonlimab plus lenvatinib versus pembrolizumab plus lenvatinib as first-line treatment in Chinese participants with advanced clear cell renal cell carcinoma (ccRCC). The primary hypotheses are (1) pembrolizumab plus belzutifan plus lenvatinib is superior to pembrolizumab plus lenvatinib with respect to progression-free survival (PFS) and overall survival (OS), in advanced ccRCC participants; and (2) pembrolizumab/quavonlimab plus lenvatinib is superior to pembrolizumab plus lenvatinib with respect to PFS and OS, in advanced ccRCC participants.

NCT ID: NCT05863052 Active, not recruiting - Melanoma Clinical Trials

Analyzing Clinical Outcomes and Genomic Data of American Indian Patient Population

Start date: January 31, 2022
Phase:
Study type: Observational

The aim of this study is to describe the outcomes in American Indian patients receiving immunotherapy in a multi-institution retrospective study at several other high-volume centers that care for this patient population and to identify any healthcare disparities that can lead to future interventional studies.

NCT ID: NCT05817604 Active, not recruiting - Renal Cancer Clinical Trials

Stereotactic Body Radiotherapy (SBRT) for Medically Inoperable Localised Renal Tumors (SABINA Trial)

SABINA
Start date: March 1, 2023
Phase:
Study type: Observational

Study evaluating the activity and efficacy of Stereotactic Body Radiotherapy for the treatment of medically inoperable localized renal cancer

NCT ID: NCT05810571 Active, not recruiting - Clinical trials for Renal Cell Carcinoma

Comparison of Postoperative Analgesic Efficacy of the Erector Spina Plane Block and Quadratus Lumborum Block in Open Nephrectomy: a Prospective Randomized Clinical Study

Start date: March 1, 2023
Phase: N/A
Study type: Interventional

patients who will undergo elective open nephrectomy will be divided into three groups; the control (PCA), the erector spina plane block, and the quadratus lumborum block. After standard anesthesia induction and monitorization then Bispectral index monitoring will be applied to all patients. Anesthesia will be maintained using sevoflurane in a mixture of oxygen and air. Continuous remifentanil infusion will be used for analgesia. Then patient's numeric rating scales and morphine pca consumptions will be recorded for one day.

NCT ID: NCT05663710 Active, not recruiting - Advanced Cancer Clinical Trials

Phase 1b/2 Study of Combination 177Lu Girentuximab Plus Cabozantinib and Nivolumab in Treatment naïve Patients With Advanced Clear Cell RCC

Start date: June 30, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

To learn if giving 177Lu girentuximab in combination with cabozantinib plus nivolumab can help to control advanced clear cell renal cell carcinoma (ccRCC).

NCT ID: NCT05579847 Active, not recruiting - Clinical trials for Renal Cell Carcinoma Stage IV

Feasibility of a Smart-Phone App for Patients With Advanced Renal Cell Carcinoma Undergoing Combination Immunotherapy

Start date: October 19, 2022
Phase:
Study type: Observational

The purpose of the study is to test and understand acceptability and preliminary effectiveness of a mobile educational app specifically customized to patients with advanced Renal Cell Carcinoma (RCC) receiving therapy with combination immunotherapy.

NCT ID: NCT05534789 Active, not recruiting - Clinical trials for Carcinoma, Renal Cell

Treatment Patterns and Clinical Outcomes Among Patients With Advanced Renal Cell Carcinoma (aRCC) Receiving Systemic First-line (1st Line) Anti-cancer Treatment Under Daily Routine in Germany: Retrospective Medical Chart Review (RENALISTIC Study).

Start date: October 15, 2022
Phase:
Study type: Observational

The purpose of this study is to learn about the treatments used in for advanced renal cell carcinoma as well as effectiveness of these treatments in the real world. Study participants must be: At least 18 years of age or older. Confirmed renal cell carcinoma Received first line treatment

NCT ID: NCT05397093 Active, not recruiting - Clinical trials for Non-small Cell Lung Cancer

ITIL-306 in Advanced Solid Tumors

Start date: August 24, 2022
Phase: Phase 1
Study type: Interventional

ITIL-306-201 is a phase 1a/1b, multicenter, clinical trial evaluating the safety and feasibility of ITIL-306 in adult participants with advanced solid tumors whose disease has progressed after standard therapy. ITIL-306 is a cell therapy derived from a participant's own tumor-infiltrating immune cells (lymphocytes; TILs) and contains a unique molecule designed to increase TIL activity when it encounters folate receptor α (FOLR1) on the tumor.

NCT ID: NCT05354102 Active, not recruiting - Clinical trials for Non-small Cell Lung Cancer

A First-in-human (FIH) Combination Treatment Study With a Single Dose Level of BMC128

Start date: May 1, 2022
Phase: Phase 1
Study type: Interventional

The purpose of this study is to assess the safety and tolerability of BMC128 in combination with nivolumab (a known immunotherapy) in order to investigate if administration of select elements of the intestinal microbiome may serve as a novel and effective means of improving the efficacy of anti-cancer immunotherapies.

NCT ID: NCT05311618 Active, not recruiting - Breast Cancer Clinical Trials

Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors

Start date: May 11, 2022
Phase: Phase 1
Study type: Interventional

Study of NGM438 as Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumors